Online inquiry

IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12758MR)

This product GTTS-WQ12758MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets NOTCH1 gene. The antibody can be applied in Lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_017617.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4851
UniProt ID P46531
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12758MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15935MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ3649MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ12293MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ4103MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ6376MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ449MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ2383MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ13404MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW